Please use this identifier to cite or link to this item:
Title: Comprimidos de liberação modificada: análise dos pedidos de patente depositados no Brasil e da utilização destes na prática do evergreening
Other Titles: Modified release tablets: analysis of patent applications filed in Brazil and their use in the evergreening of pharmaceutical patents
Advisor: Gemal, Andre Luis
Reis, André Luis de Almeida dos
Members of the board: Marin, Victor Augusto
Quental, Cristiane Machado
Caetano, Mônica Fontes
Gemal, Andre Luis
Reis, André Luis de Almeida dos
Authors: Zalfa, Viviane Mega de Andrade
Affilliation: Fundação Oswaldo Cruz. Instituto Nacional de Controle de Qualidade em Saúde
Abstract: Since 1945, Brazil did not issue pharmaceutical patents. This situation has change following the new Industrial Property Law (LPI nº. 9279/96) enactment in 14/05/1996, according to TRIPS Agreement disposal on patentability of all technological sectors. By one hand, pharmaceutical patents are an important mechanism to encourage innovation. By the other, they create monopolies, ensuring pharmaceutical companies the power to establish high prices during the protection period. Also, they delay the introduction of generic competitors into the market, which could enhance access to medicines. Brazilian National Health Surveillance Agency (ANVISA) participates in the examination of pharmaceutical patent applications by means of a legal mechanism of “prior consent”. This examination is aimed at a more restrictive interpretation of patentability criteria. The goal is not to enact undue patents, which do not aggregate any technological or therapeutic advance, but generally contributes to improperly extend market exclusivity of pharmaceutical products. Secondary patents on new pharmaceutical dosage forms are one kind of market exclusivity extension, as may be the case for modified release tablets. This work analyzes the profile of patent applications filed in Brazil for modified release tablets from 01/01/95 to 31/12/07. Applications were searched in the European Patent Office and in the Brazilian National Institute of Indústrial Property databases. Analysis was aimed at investigating whether the development of these formulations would be justifiable by a therapeutic advance point of view or would only serve as strategies of market dominance. Results showed that the United States, along with European countries, were responsible for 80% of the applications, while only 1% were carried out by Brazilians. Most of applications for modified release tablets were directed for active ingredients acting in the nervous system (33.3%), in the alimentary treat and metabolism (16.4%), and in the cardiovascular system (15.5%). Detailed analysis of patent applications identified cases where this kind of formulation is useful, even crucial, as is the case of proton pump inhibitors. Nevertheless, it was also observed that in most situations this kind of incremental modification does not represent a real advance, being only a patent extension strategy.
DeCS: comprimidos de liberação modificada
Preparações Farmacêuticas
patentes farmaceuticas
Vigilância Sanitária
Issue Date: 2008
Citation: ZALFA, V. M. A. Comprimidos de liberação modificada: análise dos pedidos de patente depositados no Brasil e da utilização destes na prática do evergreening. 2008. 137 f. Dissertação (Mestrado em Vigilância Sanitária)- Instituto Nacional de Controle de Qualidade em Saúde, Fundação Oswaldo Cruz, Rio de Janeiro, 2008.
Date of defense: 2008-09-01
Place of defense: Rio de Janeiro/RJ
Department: Coordenação de Pós-Graduação
Defense institution: Fundação Oswaldo Cruz. Instituto Nacional de Controle de Qualidade em Saúde
Program: Programa de Pós-Graduação em Vigilância Sanitária
Copyright: open access
Appears in Collections:INCQS - Dissertações de Mestrado

Files in This Item:
File Description SizeFormat 
87.pdf676.28 kBAdobe PDFView/Open

FacebookTwitterDeliciousLinkedInGoogle BookmarksBibTex Format mendeley Endnote DiggMySpace

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.